| Literature DB >> 36185533 |
Oumaporn Rungsuriyawiboon1, Thitichai Jarudecha1, Supa Hannongbua2, Kiattawee Choowongkomon3, Chaiwat Boonkaewwan4, Jatuporn Rattanasrisomporn5.
Abstract
Background and Aim: Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are retroviruses associated with chronic and neoplastic diseases in domestic and non-domestic cats. There has been increasing interest in the clinical importance of feline retroviruses in Thailand and the identification of associated risk factors in domestic cats. To prevent the spread of retroviral diseases and improve the management of retrovirus-infected cats, risk factors and associated clinical laboratory data must be clearly understood. This study aimed to identify the influence of household, lifestyle, health status, sterilization, clinical presentations, and laboratory findings on FIV- and FeLV-infected cats in Bangkok, Thailand. Materials andEntities:
Keywords: feline immunodeficiency virus; feline leukemia virus; hematology; risk factors; serum biochemistry
Year: 2022 PMID: 36185533 PMCID: PMC9394130 DOI: 10.14202/vetworld.2022.1601-1609
Source DB: PubMed Journal: Vet World ISSN: 0972-8988
Descriptive characteristics of the FeLV+, FIV+, FeLV/FIV+cats, and controls.
| 1Variable | FeLV+ (n = 60) | FIV+ (n = 40) | FeLV/FIV+ (n = 13) | Controls (n = 86) |
|---|---|---|---|---|
| Sex, no. (%) | ||||
| Male | 35 (58.3%) | 22 (55.0%) | 10 (76.9%) | 51 (59.3%) |
| Female | 25 (41.7%) | 18 (45.0%) | 3 (23.1%) | 35 (40.7%) |
| Age (year) | ||||
| Median (range) | 3.75 (0.3–8.1) | 7.04 (1–17.25) | 5.08 (1.08–13) | 3 (0.4–11) |
| Breed, no. (%) | ||||
| Domestic shorthair | 58 (96.7%) | 39 (97.5%) | 13 (100.0%) | 76 (89.4%) |
| Persian | 2 (3.3%) | 1 (2.5%) | 0 | 7 (8.2%) |
| American wirehair | 0 | 0 | 0 | 2 (2.4%) |
| Body weight (kg) | ||||
| Mean (SD) | 3.77 (1.10) | 3.89 (1.19) | 4.58 (1.39) | 4.90 (1.29) |
| Body condition score | ||||
| Median (range) | 3 (1–5) | 3 (2–5) | 3 (1–4) | 4 (1–5) |
| Sterilization, no. (%) | ||||
| Neutered | 25 (41.7%) | 10 (25.0%) | 6 (46.2%) | 4 (14.3%) |
| Intact | 33 (58.3%) | 30 (75.0%) | 7 (53.9%) | 24 (85.7%) |
| Health status, no. (%) | ||||
| Healthy | 2 (3.8%) | 6 (16.2%) | 0 | 68 (81.0%) |
| Sick | 51 (96.2%) | 31 (83.8%) | 13 (100.0%) | 16 (19.1%) |
| Ownership, no. (%) | ||||
| Pet | 25 (64.1%) | 25 (62.5%) | 9 (69.2%) | 75 (96.2%) |
| Stray | 14 (35.9%) | 15 (37.5%) | 4 (30.8%) | 3 (3.9%) |
| Lifestyle, no. (%) | ||||
| Indoor | 19 (50.0%) | 12 (30.0%) | 0 | 16 (59.3%) |
| Outdoor | 19 (50.0%) | 28 (70.0%) | 13 (100.0%) | 11 (40.7%) |
| Habitat, no. (%) | ||||
| Townhouse | 7 (18.9%) | 6 (16.2%) | 3 (25.0%) | 8 (30.8%) |
| House | 20 (54.1%) | 27 (73.0%) | 9 (75.0%) | 15 (57.7%) |
| Apartment | 10 (27.0%) | 4 (10.8%) | 0 | 2 (7.7%) |
| Market | 0 | 0 | 0 | 1 (3.9%) |
| Household, no. (%) | ||||
| One cat | 11 (29.7%) | 14 (35.9%) | 3 (23.1%) | 2 (6.9%) |
| More than 1 cat | 26 (70.3%) | 25 (64.1%) | 10 (76.9%) | 27 (93.1%) |
| Behavior, no. (%) | ||||
| Non-aggressive | 30 (81.1%) | 16 (40.0%) | 5 (38.5%) | 24 (92.3%) |
| Aggressive | 7 (18.9%) | 24 (60.0%) | 8 (61.5%) | 2 (7.7%) |
FeLV+=Feline leukemia virus positive, FIV+=Feline immunodeficiency virus positive
Multivariate analysis comparing risk factors associated with FeLV+, FIV+, and FeLV/FIV+cats.
| Variable | FeLV+ | FIV+ | FeLV/FIV+ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||||||
| n (%) | OR | 95% CI | p-value | n (%) | OR | 95% CI | p-value | n (%) | OR | 95% CI | p-value | |
| Lifestyle | ||||||||||||
| Indoor | 19 (50.0) | 1.0 | (Reference category) | 0.757 | 12 (30.0) | 1.0 | (Reference category) | 0.132 | 0 | 1.0 | (Reference category) | |
| Outdoor | 19 (50.0) | 1.22 | 0.35–4.27 | 28 (70.0) | 2.56 | 0.75–8.70 | 13 (100.0) | N/A | N/A | |||
| Household | ||||||||||||
| One cat | 11 (29.7) | 1.0 | (Reference category) | 0.041 | 14 (35.9) | 1.0 | (Reference category) | 0.05 | 3 (23.1) | 1.0 | (Reference category) | 0.457 |
| Multi-cats | 26 (70.3) | 0.17 | 0.03–0.93 | 25 (64.1) | 0.19 | 0.03–1.06 | 10 (76.9) | 0.45 | 0.06–3.62 | |||
| Habitat | ||||||||||||
| House | 20 (54.1) | 1.0 | (Reference category) | 0.676 | 27 (73.0) | 1.0 | (Reference category) | 0.152 | 9 (75.0) | 1.0 | (Reference category) | 0.776 |
| Townhouse | 7 (18.9) | 0.73 | 0.17–3.12 | 0.05 | 6 (16.2) | 0.33 | 0.07–1.51 | 0.339 | 3 (25.0) | 0.76 | 0.12–4.83 | |
| Apartment | 10 (27.0) | 6.43 | 1.00–41.31 | 4 (10.8) | 2.61 | 0.36–18.71 | 0 | N/A | N/A | |||
| Market | 0 | N/A | N/A | 0 | N/A | N/A | 0 | N/A | N/A | |||
| Owner ship | ||||||||||||
| Owned cats | 25 (64.1) | 1.0 | (Reference category) | 0.011 | 25 (62.5) | 1.0 | (Reference category) | 0.009 | 9 (69.2) | 1.0 | (Reference category) | 0.091 |
| Strayed cats | 14 (35.9) | 9.17 | 1.67–50.48 | 15 (37.5) | 9.42 | 1.75–50.66 | 4 (30.8) | 5.81 | 0.75–44.81 | |||
| Sterilization | ||||||||||||
| Neuterized | 33 (58.3) | 1.0 | (Reference category) | 0.093 | 30 (75.0) | 1.0 | (Reference category) | 0.598 | 7 (53.9) | 1.0 | (Reference category) | 0.120 |
| Intact | 25 (41.7) | 3.67 | 0.81–16.73 | 10 (25.0) | 1.53 | 0.31–7.41 | 6 (46.2) | 4.24 | 0.68–26.30 | |||
Significant difference, comparison of odds ratio between experimental categories and reference category. Odds ratios are calculated using multinomial logistic regression analysis. p < 0.05 was considered statistically significant. N/A is not applicable. FeLV+=Feline leukemia virus positive, FIV+=Feline immunodeficiency virus positive,
OR = Odds ratio, CI=Confidence interval
Figure-1Odds ratios with 95% confidence interval of risk factors for FeLV+, FIV+, and FeLV/FIV+ cats. FeLV+=Feline leukemia virus positive and FIV+=Feline immunodeficiency virus positive.
The proportion of clinical signs associated with FeLV+, FIV+, and FeLV/FIV+cats.
| Clinical signs, n (%) | FeLV+ | FIV+ | Both+ | Clinical signs, n (%) | FeLV+ | FIV+ | Both+ |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| n = 60 | n = 40 | n = 13 | n = 60 | n = 40 | n = 13 | ||
| Ophthalmological sign | Immune system | ||||||
| Conjunctivitis | 3 (5.0) | - | 1 (7.7) | Mediastinal lymphoma | 9 (15.0) | - | - |
| Ocular discharge | 1 (1.7) | 1 (2.5) | 1 (7.7) | T-cell lymphoma | 3 (5.0) | 2 (5.0) | 1 (7.7) |
| Chemosis | - | - | 1 (7.7) | B-cell lymphoma | - | 1 (2.5) | - |
| Chorioretinitis | - | 1 (2.5) | - | Lymph node enlargement | 9 (15.0) | 4 (10.0) | 1 (7.7) |
| Urinary system | Integument system | ||||||
| Urinary incontinence | - | 2 (5.0) | - | Dermatitis | 1 (1.7) | - | 1 (7.7) |
| Nephritis | - | 1 (2.5) | 1 (7.7) | Otitis externa | 1 (1.7) | - | - |
| Proteinuria | - | 1 (2.5) | - | Abscess | - | 2 (5.0) | - |
| Chronic kidney disease | - | 1 (2.5) | - | ||||
| Respiratory system | Gastrointestinal system | ||||||
| Nasal discharge | 3 (5.0) | 1 (2.5) | - | Stomatitis | 6 (10.0) | 6 (15.0) | - |
| Pleural effusion | 8 (13.3) | 4 (10.0) | - | Vomit | 6 (10.0) | 1 (2.5) | 1 (7.7) |
| Sneezing | - | 2 (5.0) | - | Regurgitation | 1 (1.7) | - | - |
| Dyspnea | 6 (10.0) | 5 (12.5) | 1 (7.7) | Gingivitis | 3 (5.0) | 3 (7.5) | 1 (7.7) |
| Tracheitis | 1 (1.7) | - | - | Peritonitis | 1 (1.7) | - | - |
| Rhinitis | 1 (1.7) | - | - | Enteritis | 1 (1.7) | - | - |
| Pneumonia | 1 (1.7) | 2 (5.0) | - | Diarrhea | - | 2 (5.0) | - |
| Lung tumor | 2 (3.3) | - | - | Halitosis | 1 (1.7) | - | - |
| Non-productive cough | 1 (1.7) | 2 (5.0) | 1 (7.7) | Ascites | - | 3 (7.5) | - |
| Hydrothorax | 1 (1.7) | - | - | Constipation | - | 1 (2.5) | - |
| Nasal cryptococcosis | - | 1 (2.5) | - | Hepatic disease | 1 (1.7) | 1 (2.5) | - |
| Epistaxis | - | 3 (7.5) | - | ||||
| Cardiology system | Endocrine system | ||||||
| Hypertrophic | - | 1 (2.5) | - | Polyuria/polydipsia | - | 1 (2.5) | - |
| cardiomyopathy Cardiac arrhythmia | - | 1 (2.5) | - | Diabetes mellitus | 1 (1.7) | - | - |
| Neurology system | Bone/muscular system | - | 1 (2.5) | - | |||
| Seizure | 1 (1.7) | - | - | Hip dysplasia | |||
| Hematology system | Non-specific sign | ||||||
| Jaundice | 1 (1.7) | - | 1 (7.7) | Pyrexia | 3 (5.0) | 1 (2.5) | - |
| Pale mucous membrane | 13 (21.7) | - | 2 (15.4) | Depress | 9 (15.0) | 4 (10.0) | - |
| Non-regenerative anemia | 1 (1.7) | - | - | Anorexia | 14 (23.3) | 4 (10.0) | 2 (15.4) |
| Thrombocytopenia | 1 (1.7) | 1 (2.5) | 1 (7.7) | Dehydrate | 9 (15.0) | 4 (10.0) | - |
| Neutropenia | - | 2 (5.0) | - | Fever | - | 1 (2.5) | - |
| Anemia | 9 (15.0) | 4 (10.0) | 3 (23.1) | Weight loss | 15 (25.0) | 17 (42.5) | 5 (38.5) |
| Eosinophilic granuloma | - | 1 (2.5) | - | Lethargy | - | 2 (5.0) | - |
FeLV+=Feline leukemia virus positive, FIV+=Feline immunodeficiency virus positive
Laboratory values and comparison of medians values between either FeLV+or FIV+, FeLV+, and FIV+ (i.e., both) and control cats.
| Variables | Control | FeLV+ | FIV+ | Both FeLV/FIV+ | p-value |
|---|---|---|---|---|---|
|
| |||||
| Median (range) | |||||
| Hemoglobin, g/dL | 12.75 (8.5–15.9)a,b,c | 9.65 (1.93–16.9)a | 10.5 (5.37–14.4)b | 9.25 (3.04–13)c | 0.0001 |
| PCV, % | 38.2 (26.2–50.0)a,b,c | 30.85 (7.13–54.6)a | 32.7 (17–41.2)b | 30.3 (7.19–40.3)c | 0.0001 |
| RBC, 106/mL | 8.15 (5.69–11.7)a,b,c | 5.41 (0.99–10.2)a,d | 6.84 (3.43–10.3) b,d,e | 5.49 (1.08– 7.89)c,e | 0.0001 |
| MCV, fL | 48.15 (31.8–65.0)a,b | 52.88 (3.97–83.08) a,c,d | 49 (15.1–73.01)c,e | 56.23 (48.42–79.45)b,d,e | 0.0001 |
| MCHC, g/dL | 32.96 (29.98–35.9) a,b,c | 31.84 (15.3–35.9)a | 32.12 (29.32–37.5)b | 31.92 (28.58–42.28)c | 0.0002 |
| MCH, pg | 15.6 (11.3–18.4)a,b | 17.1 (8.99–33.4)a,c,d | 15.81 (9.34–23.48)c | 17.3 (15.34–28.15)b,d | 0.0001 |
| RDW, % | 20.1 (11.8–25.6)a,b | 21.5 (16.5–60.6)a,c | 19.8 (16–29.2)c,d | 22 (18.7–51.5)b,d | 0.0020 |
| WBC, 103/mL | 10.7 (4.72–33.0) | 10.65 (1.98–37.6) | 10.2 (3.57–41.2) | 6.99 (1.38–36.0) | 0.5453 |
| Neutrophil, 103/mL | 72 (38–95) | 81.5 (10–97) | 77.5 (7–95) | 78 (60–97) | 0.0673 |
| Lymphocyte, 103/mL | 18.5 (3–60) | 13 (1–82) | 12 (1–81) | 16 (3–30) | 0.2839 |
| Monocyte, 103/mL | 4 (1–30)a,b | 2 (0–10)a,c | 5 (0–12)c | 1 (0–7)b | 0.0205 |
| Eosinophil, 103/mL | 5 (1–18)a,b | 3 (0–17)a | 3 (0–19)b | 3 (0–9) | 0.0042 |
| Platelet, 103/mL | 300 (53.5–1604)a,b | 246 (7.2–712)a | 300 (13.4–620)c | 120 (28.4–620)b,c | 0.0128 |
| BUN, mg/dL | 24 (13–65.8) | 24.5 (9–49) | 28 (13–167) | 21 (13–105) | 0.2033 |
| Creatinine, mg/dL | 1.47 (0.73–56.0) | 1.34 (0.69–2.22) | 1.48 (0.68–9.47) | 1.62 (0.74–3.33) | 0.0622 |
| ALT, IU/L | 61 (17–716) | 55 (18–415) | 46 (18–461) | 54 (25–132) | 0.0776 |
| Albumin, g/dL | 3.5 (2.7–4.1)a,b | 3.2 (2.2–4.2)c | 3.4 (2.4–3.7)a,c | 3.1 (2–7)b | 0.0002 |
| γ-globulins, g/dL | 4.3 (0–7.4)a,b | 3.6 (2.6–6.2)a,c,d | 5 (2.9–10.1)b,c | 4.7 (0.3–5.4)d | 0.0001 |
| Total protein | 7.7 (6–9.6)a | 7.1 (5.2–9.8)a,b | 8 (5.9–12.7)b | 7.4 (6.4–8.3) | 0.0038 |
a–e are upper alphabet that paired same letter for being significant difference of median between groups,
Indicates a significant difference (the minimum significance value chosen was p < 0.05). A comparison of the median (range) of all groups was performed using the Kruskal–Wallis test, upper alphabet (paired same meaning significant difference) comparison of median between groups was performed using two-sample Wilcoxon rank-sum
(Mann–Whitney) test. p < 0.05 was considered statistically significant. PCV=Packed cell volume, RBC=Red blood cell, MC=Mean corpuscular volume, MCHC=Mean corpuscular hemoglobin concentration, MCH=Mean corpuscular hemoglobin, RDW=Red cell distribution width, WBC=White blood cell, BUN=Blood urea nitrogen, ALT=Alanine amino transferase, FeLV+=Feline leukemia virus positive, FIV+=Feline immunodeficiency virus positive